Plasma rich in growth factor gel as an autologous filler for facial volume restoration.


Journal

Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 07 06 2019
revised: 02 12 2019
accepted: 22 01 2020
pubmed: 12 2 2020
medline: 11 5 2021
entrez: 12 2 2020
Statut: ppublish

Résumé

Skin aging is characterized by moderate to severe wrinkles, laxity, roughness, and volume loss as a result of cutaneous atrophy and connective tissue degradation. Plasma rich in growth factor gel (PRGF-gel) is a novel formulation obtained from the patient's own blood that has demonstrated optimal biomechanical and bioactive properties for soft tissue restoration. Following a retrospective design, the clinical safety and efficacy of PRGF-gel for facial volume restoration and skin rejuvenation were evaluated. Twenty women clinically diagnosed for aged skin symptoms were treated with PRGF-gel. Participants received an individualized regimen depending on their therapeutic needs. At the end of the follow-up periods, clinical performance analysis was evaluated by standardized macrophotographs along with clinical and patient surveys based on Likert's scales. Based on their initial expectations, patients referred to be highly satisfied after PRGF-gel treatment in terms of fine line amelioration, wrinkle reduction, and sagging improvement (overall satisfaction of 8/10). Pre/post-photograph clinical evaluation showed an improvement of 2.5/3 and patients presented a noticeable face rejuvenation due to the soft tissue augmentation effect which was translated into surface texture softening and tone recovery. Although additional randomized clinical trials should be carried out, this study provides preliminary data supporting the use of PRGF-gel for facial volume restoration.

Sections du résumé

BACKGROUND BACKGROUND
Skin aging is characterized by moderate to severe wrinkles, laxity, roughness, and volume loss as a result of cutaneous atrophy and connective tissue degradation. Plasma rich in growth factor gel (PRGF-gel) is a novel formulation obtained from the patient's own blood that has demonstrated optimal biomechanical and bioactive properties for soft tissue restoration.
OBJECTIVES OBJECTIVE
Following a retrospective design, the clinical safety and efficacy of PRGF-gel for facial volume restoration and skin rejuvenation were evaluated.
METHODS METHODS
Twenty women clinically diagnosed for aged skin symptoms were treated with PRGF-gel. Participants received an individualized regimen depending on their therapeutic needs. At the end of the follow-up periods, clinical performance analysis was evaluated by standardized macrophotographs along with clinical and patient surveys based on Likert's scales.
RESULTS RESULTS
Based on their initial expectations, patients referred to be highly satisfied after PRGF-gel treatment in terms of fine line amelioration, wrinkle reduction, and sagging improvement (overall satisfaction of 8/10). Pre/post-photograph clinical evaluation showed an improvement of 2.5/3 and patients presented a noticeable face rejuvenation due to the soft tissue augmentation effect which was translated into surface texture softening and tone recovery.
CONCLUSIONS CONCLUSIONS
Although additional randomized clinical trials should be carried out, this study provides preliminary data supporting the use of PRGF-gel for facial volume restoration.

Identifiants

pubmed: 32045103
doi: 10.1111/jocd.13322
doi:

Substances chimiques

Intercellular Signaling Peptides and Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2552-2559

Informations de copyright

© 2020 Wiley Periodicals, Inc.

Références

Zouboulis CC, Makrantonaki E. Clinical aspects and molecular diagnostics of skin aging. Clin Dermatol. 2011;29(1):3-14.
Coleman SR, Grover R. The anatomy of the aging face: volume loss and changes in 3-dimensional topography. Aesthet Surg J. 2006;26(1):S4-S9.
Wan D, Amirlak B, Rohrich R, Davis K. The clinical importance of the fat compartments in midfacial aging. Plast Reconstr Surg Glob Open. 2013;1(9):e92.
de Maio M. Myomodulation with injectable fillers: an innovative approach to addressing facial muscle movement. Aesthetic Plast Surg. 2018;42(3):798-814.
Attenello NH, Maas CS. Injectable fillers: review of material and properties. Facial Plast Surg. 2015;31(1):29-34.
Chiang YZ, Pierone G, Al-Niaimi F. Dermal fillers: pathophysiology, prevention and treatment of complications. J Eur Acad Dermatol Venereol. 2017;31(3):405-413.
Anitua E, Pino A, Troya M, Jaen P, Orive G. A novel personalized 3D injectable protein scaffold for regenerative medicine. J Mater Sci Mater Med. 2017;29(1):7.
Fedyakova E, Pino A, Kogan L, Eganova C, Troya M, Anitua E. An autologous protein gel for soft tissue augmentation: in vitro characterization and clinical evaluation. J Cosmet Dermatol. 2019;18(3):762-772.
Wollina U. Midfacial rejuvenation by hyaluronic acid fillers and subcutaneous adipose tissue-a new concept. Med Hypotheses. 2015;84(4):327-330.
D'Esposito V, Passaretti F, Perruolo G, et al. Platelet-rich plasma increases growth and motility of adipose tissue-derived mesenchymal stem cells and controls adipocyte secretory function. J Cell Biochem. 2015;116(10):2408-2418.
Romaldini A, Mastrogiacomo M, Cancedda R, Descalzi F. Platelet lysate activates human subcutaneous adipose tissue cells by promoting cell proliferation and their paracrine activity toward epidermal keratinocytes. Front Bioeng Biotechnol. 2018;6:203.
Jiménez Gómez N, Pino Castresana A, Segurado Miravalles G,, et al. Autologous platelet-rich gel for facial rejuvenation and wrinkle amelioration: a pilot study. J Cosmet Dermatol. 2019;18(5):1353-1360.
Sánchez M, Fiz N, Azofra J, et al. A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis. Arthroscopy. 2012;28(8):1070-1078.
Anitua E, Sanchez M, Orive G, Andia I. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials. 2007;28(31):4551-4560.
Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants. 1999;14(4):529-535.
Anitua E, Aguirre JJ, Algorta J, et al. Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomed Mater Res B Appl Biomater. 2008;84(2):415-421.
Hirsch RJ, Narurkar V, Carruthers J. Management of injected hyaluronic acid induced Tyndall effects. Lasers Surg Med. 2006;38(3):202-204.
Centeno AF-T, Roldán FA, Álvarez IB, Sánchez RR, Fernández CV. Bioestimulación cutánea con plasma rico en plaquetas autólogo. Estudio controlado con ecografía. Piel. 2013;28(2):69-74.
Quatresooz P, Pierard-Franchimont C, Kharfi M, et al. Skin in maturity: the endocrine and neuroendocrine pathways. Int J Cosmet Sci. 2007;29(1):1-6.
Anitua E, Pino A, Jaen P, Orive G. Plasma rich in growth factors enhances wound healing and protects from photo-oxidative stress in dermal fibroblasts and 3D skin models. Curr Pharm Biotechnol. 2016;17(6):556-570.
Anitua E, Pino A, Orive G. Plasma rich in growth factors inhibits ultraviolet B induced photoageing of the skin in human dermal fibroblast culture. Curr Pharm Biotechnol. 2016;17(12):1068-1078.
Diaz-Ley B, Cuevast J, Alonso-Castro L, et al. Benefits of plasma rich in growth factors (PRGF) in skin photodamage: clinical response and histological assessment. Dermatol Ther. 2015;28(4):258-263.

Auteurs

Lisa Godfrey (L)

The Castle Clinic, Nottingham, UK.

Jorge Martínez-Escribano (J)

Openderma-Clínica Dermatológica, Murcia, Spain.

Elia Roo (E)

Clider-Clínica Dermatológica Roo, Madrid, Spain.

Ander Pino (A)

BTI-Biotechnology Institute, Vitoria, Spain.

Eduardo Anitua (E)

BTI-Biotechnology Institute, Vitoria, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH